RE: ViviDion bought out by Bayer ?22 Sep 2021 20:36
We're currently priced about £5m above cash level so based on that the market certainly agrees with you.
But you also have to bear in mind the general market as a whole has been very poor for at least 2 months too.
If Huw can keep the newsflow coming on glioma as planned, with the pre-IND meeting next (hopefully first half of Q4) followed by IND submission, and with an improving market generally I think interest will start to pick up and the value might start to anticipate some of the potential. With Kight picking up a large part of the already tight free float then it's not going to take much.